Compare Enbridge Inc (ENB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Enbridge Inc trades at $46.6 (market cap $103.38B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Enbridge Inc is far larger — about 10.2× State Street SPDR S&P Biotech ETF's market cap, and Enbridge Inc pays a 6.02% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| ENB | XBI | |
|---|---|---|
Market Cap | $103.38B | $10.11B |
Volume | 3,684,305 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $58.04 | $169.55 |
52-Week Low | $45.23 | $104.99 |
Typical Hold Time | 91 Days | 38 Days |
Enterprise Value | $185.39B | — |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $46.54, up 1.42% on the day, with a bearish technical signal from moving averages. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.46 surpassing the $0.43 estimate. The company maintains a solid dividend yield, with a $0.97 payment scheduled for September 2026. Revenue grew to $65.19B in 2025, and net income reached $7.49B, though profit margins have fluctuated. Analyst consensus is mixed, with a $61.63 price target suggesting significant upside from current levels.
The outlook for ENB is cautiously optimistic, supported by earnings beats and a strong dividend, but tempered by bearish technicals and rising debt levels. Investment appeal lies in its stable cash flows and growth backlog, while risks include interest rate sensitivity and execution of capital projects. The stock presents a value opportunity if it can navigate macroeconomic headwinds and maintain operational performance.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
